In BRCA2, the highest cumulative risk was also breast cancer at 58.3% (95% CI, 38.3%-71.9%), followed by prostate cancer at 24.5% (95% CI, 6.9%-38.8%), gastric cancer at 19.3% (95% CI, 11.9%-26.0%), ovarian cancer at 14.8% (95% CI, 4.6%-23.9%), pancreatic cancer at 13.7% (95% CI, 3.7%-22.8%), and esophageal cancer at 5.2% (95% CI, 1.7%-8.5%). This evidence concerns the gene BRCA2 and prostate cancer.